Trial · NCT00696878
Results by group285
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 285
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Clinically Relevant Immunogenicity | Corifollitropin Alfa 150 µg | Cycle 1 (n=681) | 0.0 | percentage of participants | |
| Percentage of Participants With Clinically Relevant Immunogenicity | Corifollitropin Alfa 150 µg | Cycle 2 (n=372) | 0.0 | percentage of participants | |
| Percentage of Participants With Clinically Relevant Immunogenicity | Corifollitropin Alfa 150 µg | Cycle 3 (n=192) | 0.0 | percentage of participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Itching and With Mild, Moderate and Severe Itching in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | None | 679 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Itching and With Mild, Moderate and Severe Itching in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Mild | 3 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Itching and With Mild, Moderate and Severe Itching in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Moderate | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Itching and With Mild, Moderate and Severe Itching in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Severe | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Pain and With Mild, Moderate and Severe Pain in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | None | 678 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Pain and With Mild, Moderate and Severe Pain in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Mild | 4 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Pain and With Mild, Moderate and Severe Pain in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Moderate | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Pain and With Mild, Moderate and Severe Pain in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Severe | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Redness and With Mild, Moderate and Severe Redness in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | None | 654 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Redness and With Mild, Moderate and Severe Redness in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Mild | 28 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Redness and With Mild, Moderate and Severe Redness in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Moderate | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Redness and With Mild, Moderate and Severe Redness in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Severe | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Swelling and With Mild, Moderate and Severe Swelling in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | None | 680 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Swelling and With Mild, Moderate and Severe Swelling in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Mild | 2 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Swelling and With Mild, Moderate and Severe Swelling in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Moderate | 0 | participants | |
| Local Tolerance at Injection Site: Number of Participants With no Event of Swelling and With Mild, Moderate and Severe Swelling in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | Severe | 0 | participants | |
Local Tolerance at Injection Site Overall Summary: Number of Participants With no Local Tolerance Event (Itching, Pain, Redness or Swelling) and With a Mild, Moderate and Severe Local Tolerance Event in Any of 3 Treatment Cycles | Corifollitropin Alfa 150 µg | None | 647 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00696878/results